Polymyxins retain in vitro activity and in vivo efficacy against “resistant” Acinetobacter baumannii strains when tested in physiological conditions
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00725-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jennifer Rubio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Microbial Sensitivity Tests, Anti-Bacterial Agents, Polymyxins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), MOHW | Food and Drug Administration (FDA).
Abstract (Originalsprache)
The emergence of plasmid-mediated resistance threatens the efficacy of polymyxins as the last line of defense against pan-drug-resistant infections. However, we have found that using Mueller-Hinton II (MHII), the standard minimum inhibitory concentration (MIC) medium, results in MIC data that are disconnected from in vivo treatment outcomes. We found that culturing putative colistin-resistant Acinetobacter baumannii clinical isolates, as defined by MICs of >2 mg/L in standard MHII testing conditions, in bicarbonate-containing media reduced MICs to the susceptible range by preventing colistin resistance-conferring lipopolysaccharide modifications from occurring. Furthermore, the lower MICs in bicarbonate-containing media accurately predicted in vivo efficacy of a human-simulated dosing strategy of colistin and polymyxin B in a lethal murine infection model for some polymyxin-resistant A. baumannii strains. Thus, current polymyxin susceptibility testing methods overestimate the contribution of polymyxin resistance-conferring mutations and incorrectly predict antibiotic activity in vivo . Polymyxins may remain a viable therapeutic option against Acinetobacter baumannii strains heretofore determined to be “pan-resistant.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
- Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USA.
- Los Angeles General Medical Center, Los Angeles, California, USA.
ORCID-Profile: Jennifer Rubio, Brian Luna
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- MOHW | Food and Drug Administration (FDA)
- NIEHS NIH HHS
Zitieren
APA
Rubio, J., Yan, J., Miller, S., Cheng, J., Li, R., Builta, Z., Aoyagi, K., Fisher, M., She, R., Spellberg, B., & Luna, B. (2024). Polymyxins retain in vitro activity and in vivo efficacy against “resistant” Acinetobacter baumannii strains when tested in physiological conditions. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00725-24
Vancouver
Rubio J, Yan J, Miller S, Cheng J, Li R, Builta Z, et al. Polymyxins retain in vitro activity and in vivo efficacy against “resistant” Acinetobacter baumannii strains when tested in physiological conditions. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00725-24
BibTeX
@article{Rubio2024,
author = {Rubio, Jennifer and Yan, Jun and Miller, Sarah and Cheng, Jiaqi and Li, Rachel and Builta, Zac and Aoyagi, Kari and Fisher, Mark and She, Rosemary and Spellberg, Brad and Luna, Brian},
title = {Polymyxins retain in vitro activity and in vivo efficacy against “resistant” Acinetobacter baumannii strains when tested in physiological conditions},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00725-24}
}
EUVIMED